학술논문
Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine.
Document Type
Letter
Author
Launay, Odile; Simon, Tabassome; de Lamballerie, Xavier; Cachanado, Marine; Luong Nguyen, Liem B; Ninove, Laetitia; Lachâtre, Marie; Ben Ghezala, Inès; Bardou, Marc; Schmidt-Mutter, Catherine; Lacombe, Karine; Laine, Fabrice; Allain, Jean-Sébastien; Botelho-Nevers, Elisabeth; Tavolacci, Marie-Pierre; Chidiac, Christian; Pavese, Patricia; Dussol, Bertrand; Priet, Stéphane; Deplanque, Dominique
Source
Subject
*BOOSTER vaccines
*CHEST pain
*SARS-CoV-2
*INFLUENZA prevention
*INFLUENZA vaccines
*IMMUNOMODULATORS
*VIRAL antibodies
*
*
*
*
*
*
Language
ISSN
0028-4793
Abstract
The article reports that The value of variant-adapted vaccines that are capable of inducing a higher and broader immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at booster vaccination is currently being evaluated.1-4 We conducted a multicenter, randomized, single-blind trial to assess the immunogenicity and safety of two adjuvanted recombinant vaccines and the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech) administered as a booster.